Onyx HealthcareROCO:6569 75 ROE % is 12.04% as of Dec. 2025, which is 27% below its 10-year median of 16.54. GuruFocus rates ROCO:6569 with a GF Score™ of 75/100 and a GF Value™ of NT$121.39 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 623 Healthcare Providers & Services companies, Onyx Healthcare ranks better than 53.61% on this metric.
The historical rank and industry rank for Onyx Healthcare's ROE % or its related term are showing as below:
ROCO:6569'
s ROE % Range Over the Past 10 Years
Min: 7.2 Med: 16.54 Max: 27.26
Current: 7.26
During the past 13 years, Onyx Healthcare's highest ROE % was 27.26%. The lowest was 7.20%. And the median was 16.54%.
ROCO:6569's ROE % is ranked better than 53.61% of 623
companies
in the Healthcare Providers & Services industry
Industry Median: 5.88
vs ROCO:6569: 7.26
Onyx Healthcare (ROCO:6569) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Onyx Healthcare ROE % Related Terms
Onyx Healthcare ROE % Historical Data
* Premium members only.
The historical data trend for Onyx Healthcare's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Onyx Healthcare's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onyx Healthcare ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Onyx Healthcare's ROE % distribution charts can be found below:
* The bar in red indicates where Onyx Healthcare's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Onyx Healthcare (ROCO:6569) has a ROE % of 12.04% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Onyx Healthcare and its competitors. This is 27% below median its historical median of 16.54. Over the past decade, Onyx Healthcare's ROE % has ranged from 7.20 to 27.26. According to the industry distribution chart, Onyx Healthcare ranks #289 out of 623 companies in the Healthcare Providers & Services industry, placing it in the top 46.4%.
Is Onyx Healthcare's ROE % too high?
Onyx Healthcare's current ROE % of 12.04% is 27% below median its 10-year median of 16.54. Over the past 10 years, this metric has ranged from a low of 7.20 to a high of 27.26. The Healthcare Providers & Services industry median ROE % is 5.88. Onyx Healthcare's value of 12.04% is 104.8% above this industry median. Based on the distribution chart, Onyx Healthcare ranks #289 out of 623 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Onyx Healthcare has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Onyx Healthcare's ROE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Onyx Healthcare ranks #289 out of 623 companies for ROE %. This puts Onyx Healthcare in the upper half of its industry. The industry median ROE % is 5.88. Onyx Healthcare's value of 12.04% is 104.8% above this benchmark. Historically, Onyx Healthcare's own ROE % has ranged from 7.20 to 27.26 over the past decade. While the company's 10-year median is 16.54 vs. the industry median of 5.88, Onyx Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.88, based on 623 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Onyx Healthcare's current ROE % of 12.04% is 104.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Onyx Healthcare and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Onyx Healthcare's current ROE % is 12.04%, which is 27% below median its own 10-year median of 16.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onyx Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Onyx Healthcare (ROCO:6569) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$121.39, compared to a current price of NT$106.50 — trading 12.3% below its estimated fair value. The current ROE % is 12.04%, which is 27% below median its 10-year median of 16.54 and 104.8% above the Healthcare Providers & Services industry median of 5.88. Onyx Healthcare's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Onyx Healthcare (ROCO:6569), the current ROE % is 12.04% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Onyx Healthcare (ROCO:6569) Overvalued in 2026?
Based on GuruFocus' analysis, Onyx Healthcare stock appears to be undervalued.
The current stock price of NT$106.50 is trading 12.3% below its estimated GF Value™ of NT$121.39.
GuruFocus considers Onyx Healthcare to be Modestly Undervalued.
Key valuation signals for ROCO:6569:
ROE %: 12.04% (27% below median its 10-year median of 16.54)
GF Value™: NT$121.39 vs. price of NT$106.50 (12.3% below fair value)
Industry Position: 104.8% above the Healthcare Providers & Services median (#289 of 623)
No single metric tells the full story. See the ROCO:6569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Onyx Healthcare Inc is engaged in designing, manufacturing, and trading of medical computers and peripherals. The company provides medical products such as AI Ready Medical PC and Tablet, Medical PC & Monitor for Digital OR (ACCEL), Telemedicine, Medical Cart Computer(Venus), Medical Power Panel PC (Mini Venus), Power Bank (UPower), Battery Management System (ORION), Mobile Medical Tablet (MD), Professional Medical All in One PC (ZEUS), etc. It operates in Taiwan, the United States, Europe, and Other countries and generates maximum revenue from Taiwan.
75GF Score
Get the complete analysis for ROCO:6569
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6569 has been successfully added to your 
